الإحصائيات الأساسية
| CIK | 1781983 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aprea Therapeutics, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 12, 2025 |
Exhibit 99.1 Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051 $16.5 million in cash and cash equivalents as of June 30, 2025 DOYLESTOWN, PA, Augu |
|
| August 12, 2025 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality August 2025 2 © 2025 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics Opportunity to Lead SL and DDR WEE1 Inhibitor: APR-1051 • Pre-clinical proof-of-principle: • Highly potent and selective • Minimal off-target effect • Phase 1 study – ongoing • Evidence of activity in early dose cohorts • Promising pharmacokinetics • Tole |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2025 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Apre |
|
| June 9, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2025 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 14, 2025 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality May 2025 2 © 2025 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our |
|
| May 14, 2025 |
Exhibit 99.1 Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2025 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Apr |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 22, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| March 25, 2025 |
Exhibit 99.1 Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; pla |
|
| March 25, 2025 |
Form of 2019 Equity Incentive Plan Restricted Stock Unit Award Notice Exhibit 10.6 Aprea Therapeutics, Inc. 2019 Equity Incentive Plan Restricted Stock Unit Award Notice You have been awarded a restricted stock unit award with respect to shares of common stock of Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan (the “Plan”) and the Restricted Stock Unit A |
|
| March 25, 2025 |
Amendment to Employment Agreement between Aprea Therapeutics, Inc. and John P. Hamill Exhibit 10.18 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is made and entered into effective as of March 25, 2025 (the “Amendment Effective Date”) between Aprea Therapeutics, Inc. (“Aprea”) and John P. Hamill (“Executive”). WHEREAS, Aprea and Executive entered into that certain Employment Agreement dated as of January 30, 2023 (the “Agreement”); WHE |
|
| March 25, 2025 |
Form of 2019 Equity Incentive Plan Stock Option Award Notice Exhibit 10.4 APREA THERAPEUTICS, INC. 2019 STOCK INCENTIVE PLAN STOCK OPTION AWARD NOTICE You have been awarded an option to purchase shares of Common Stock of Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Aprea Therapeutics, Inc. 2019 Stock Incentive Plan (the “Plan”) and the Stock Option Agreement (together with this Award Notice, t |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2025 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| March 25, 2025 |
Form of 2019 Equity Incentive Plan Stock Option Agreement Exhibit 10.3 APREA THERAPEUTICS, INC. 2019 STOCK INCENTIVE PLAN Stock Option Agreement Aprea Therapeutics, Inc., a Delaware corporation (the ”Company”), hereby grants to the individual (“Holder”) named in the award notice attached hereto (the ”Award Notice”) as of the date set forth in the Award Notice, pursuant to the provisions of the Aprea Therapeutics, Inc. 2019 Stock Incentive Plan (the “Plan |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Aprea Therapeutic |
|
| March 25, 2025 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality March 2025 2 © 2025 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to ou |
|
| March 25, 2025 |
Form of 2019 Equity Incentive Plan Restricted Stock Unit Award Agreement Exhibit 10.5 Aprea Therapeutics, Inc. 2019 Equity Incentive Plan RESTRICTED STOCK UNIT AWARD AGREEMENT Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants to the individual (the “Holder”) named in the award notice attached hereto (the “Award Notice”) as of the date set forth in the Award Notice (the “Grant Date”), pursuant to the provisions of the Aprea Therapeutics, In |
|
| February 13, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EX-99.1 AGREEMENT 2 apre13ga1.htm EXHIBIT 99 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 19 |
|
| February 5, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 5, 2025 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| February 5, 2025 |
Exhibit 99.1 Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics DOYLESTOWN, PA, February 5, 2025 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to he |
|
| January 13, 2025 |
Exhibit 99.1 Precision Oncology Through Synthetic Lethality January 2025 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 13, 2025 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| November 8, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-276702 PROSPECTUS SUPPLEMENT (To prospectus dated February 2, 2024) Up to $3,000,000 Common Stock We have entered into an At The Market Offering Agreement (the “sales agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) relating to shares of our common stock, par value $0.001 per share, offered by this prospe |
|
| November 8, 2024 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT November 8, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Aprea Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, w |
|
| November 8, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 8, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| November 7, 2024 |
Exhibit 10.1 Confidential Severance Agreement And general Release This Confidential Severance Agreement and General Release (“Agreement”) is made by and between Nadeem Mirza, M.D., M.P.H. (“Employee”) and Aprea Therapeutics, Inc., a Delaware corporation (“Company”) (collectively, the “Parties”). WHEREAS, Employee was employed by Company pursuant to that certain Employment Agreement dated April 30, |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 |
|
| November 7, 2024 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality November 2024 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| November 7, 2024 |
Exhibit 99.1 Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities Philippe Pultar, MD engaged as senior medical advisor to support the development and advancement of APR-1051 $26.2 million in cash and cash |
|
| October 23, 2024 |
Exhibit 99.1 Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is ongoing at three sites in the U.S. Preliminary results to date demonstra |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 23, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| October 10, 2024 |
APRE / Aprea Therapeutics, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aprea Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03836J201 (CUSIP Number) October 7, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| October 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 9, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| October 9, 2024 |
Exhibit 99.1 Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development DOYLESTOWN, PA, October 09, 2024 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pu |
|
| August 21, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Aprea Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 Rule 457(c) and Rule 457(h) 149,466(5) $3.505 $523,878 |
|
| August 21, 2024 |
As filed with the Securities and Exchange Commission on August 21, 2024 Registration No. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Apre |
|
| August 12, 2024 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality August 2024 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to o |
|
| August 12, 2024 |
Exhibit 99.1 Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash equivalents as of June 30, 2024 with cash runway extended into Q4 2025 DOYLESTOWN, PA, August 1 |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| June 20, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 20, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission F |
|
| June 17, 2024 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality June 2024 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our |
|
| June 17, 2024 |
Exhibit 99.1 Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study repr |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 17, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission F |
|
| May 14, 2024 |
Exhibit 10.5 APREA THERAPEUTICS, INC. INDUCEMENT STOCK OPTION AWARD NOTICE Nadeem Q. Mirza, M.D., M.P.H. You have been awarded a non-qualified option to purchase shares of Common Stock of Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), as an inducement material to your acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Gra |
|
| May 14, 2024 |
Exhibit 99.1 Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024 First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation in ABOYA-119 clinical tr |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Apr |
|
| May 14, 2024 |
Exhibit 10.6 Aprea Therapeutics, Inc. Inducement Restricted Stock Unit Award Notice Nadeem Q. Mirza, M.D., M.P.H. You have been awarded a restricted stock unit award (each an “RSU” and collectively, the “RSUs”) of Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), as an inducement material to your acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635( |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 14, 2024 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality May 2024 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our |
|
| May 14, 2024 |
Exhibit 10.4 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) between APREA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and Nadeem Q. Mirza, M.D., M.P.H. (the “Executive”), is made and entered into as of April 30, 2024 and shall become effective May 1, 2024 (the “Effective Date”). WHEREAS, the Company and NM BioConsulting, LLC (“Consultant”) are parties to a Consult |
|
| April 30, 2024 |
PROSPECTUS APREA THERAPEUTICS, INC. 4,389,576 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-278485 PROSPECTUS APREA THERAPEUTICS, INC. 4,389,576 Shares of Common Stock This prospectus relates to the possible resale, from time to time, by the selling stockholders identified in this prospectus of up to (i) 1,687,712 shares of our common stock, par value $0.001 per share (the “Common Stock”), initially issued in a pri |
|
| April 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 25, 2024 |
APREA THERAPEUTICS, INC. 3805 Old Easton Road Doylestown, PA 18902 APREA THERAPEUTICS, INC. 3805 Old Easton Road Doylestown, PA 18902 April 25, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Aprea Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-278485 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 10, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| April 10, 2024 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality April 2024 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to ou |
|
| April 10, 2024 |
Exhibit 99.1 Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; |
|
| April 3, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) APREA THERAPEUTICS, INC. |
|
| April 3, 2024 |
As filed with the Securities and Exchange Commission on April 3, 2024. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 3, 2024. |
|
| March 26, 2024 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality March 2024 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to ou |
|
| March 26, 2024 |
Aprea Therapeutics, Inc. Insider Trading Policy. Exhibit 19 APREA THERAPEUTICS, INC. INSIDER TRADING POLICY As adopted by the Board of Directors as of September 28, 2023 Exhibit 19 Table of Contents Page Section 1. All Employees, Officers, Directors and their Family Members and Affiliates Are Subject to this Policy1 Section 2. Trading in Aprea Securities while in Possession of Material Nonpublic Information Is Prohibited1 Section 3. Trading Wi |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Aprea Therapeutic |
|
| March 26, 2024 |
Exhibit 99.1 Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate P |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 26, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| March 26, 2024 |
Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Aprea Therapeutics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, par value $0.001 per share (the “common stock”). For purposes of this exhibit, unless the context otherw |
|
| March 26, 2024 |
Subsidiaries of Aprea Therapeutics, Inc. Exhibit 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Aprea Therapeutics AB Sweden Aprea US, Inc. Delaware ATR Pharmaceuticals LLC Delaware |
|
| March 26, 2024 |
Aprea Therapeutics, Inc. Policy for Recovery of Erroneously Awarded Incentive Compensation. Exhibit 97 APREA THERAPEUTICS, INC. Policy for RECOVERY OF ERRONEOUSLY AWARDED Incentive Compensation (Adopted October, 2023) 1. INTRODUCTION Aprea Therapeutics, Inc. (the “Company”) is adopting this policy (this “Policy”) to provide for the Company’s recovery of certain Incentive Compensation (as defined below) erroneously awarded to Affected Officers (as defined below) under certain circumstance |
|
| March 12, 2024 |
Exhibit 99.1 Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 million in potential warrant exercise proceeds for an aggregate of up to $34.0 million in to |
|
| March 12, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 12, 2024 |
Exhibit 10.3 PLACEMENT AGENCY AGREEMENT March 11, 2024 Oren Gilad, Ph.D. Chief Executive Officer Aprea Therapeutics, Inc. 3805 Old Easton Road Doylestown, Pennsylvania 18902 Dear Oren: This agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) Aprea Therapeutics, Inc., Inc., a Delaware corporation (the “Company”), that Maxim shall serve as |
|
| March 12, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March [ ], 2024, by and among Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), and the parties signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to that certain Securities Purchase A |
|
| March 12, 2024 |
Exhibit 99.2 Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers Company plans to initiate Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) clinical trial evaluating, highly selective, oral WEE1 inhibitor, for monotherapy treatment of Cyclin E |
|
| March 12, 2024 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 12, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 11, 2024, between Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 11, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| March 12, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 14, 2024 |
US03836J2015 / APREA THERAPEUTICS INC / Sio Capital Management, LLC Passive Investment SC 13G 1 g19242sc13g.htm CUSIP No. 03836J201 Page 1 of 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Aprea Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 03836J201 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 9, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-276702 PROSPECTUS SUPPLEMENT (To prospectus dated February 2, 2024) Up to $2,000,000 Common Stock We have entered into an At The Market Offering Agreement (the “sales agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) relating to shares of our common stock, par value $0.001 per share, offered by this prospe |
|
| February 7, 2024 |
APRE / Aprea Therapeutics, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 ApreaTherapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03836J102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 6, 2024 |
Exhibit 99.1 Precision Oncology Through Synthetic Lethality February 2024 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to |
|
| February 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 6, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| February 5, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-276702 Up to $1,000,000 Common Stock We have entered into an At The Market Offering Agreement (the “sales agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectus. In accordanc |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 2, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| January 31, 2024 |
Aprea Therapeutics, Inc. 3805 Old Easton Road Doylestown, PA 18902 Aprea Therapeutics, Inc. 3805 Old Easton Road Doylestown, PA 18902 January 31, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards RE: Aprea Therapeutics, Inc. Registration Statement on Form S-3 Filed January 26, 2024 File No. 333-276702 Acceleration Request Dear Mr. Edwards: With respect |
|
| January 26, 2024 |
As filed with the Securities and Exchange Commission on January 26, 2024. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 26, 2024. |
|
| January 26, 2024 |
Exhibit 4.1 APREA THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 3 Section 1.3. Incorporation by Reference of Trust Indenture Act 3 Section 1.4. Rules of Construction 3 ARTICLE II. THE SECURITIES 3 Section 2.1. Issuable in Series 3 Section 2.2. Establi |
|
| January 26, 2024 |
Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT January 26, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Aprea Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, wh |
|
| January 26, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 26, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| January 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Aprea Therapeutics, Inc. |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 4, 2024 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| January 4, 2024 |
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 Exhibit 99.1 Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 DOYLESTOWN, Pa., January 4, 2024 – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and plans for advancement of |
|
| January 4, 2024 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality January 2024 2 © 2024 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to |
|
| November 9, 2023 |
Exhibit 99.2 Precision Oncology Through Synthetic Lethality November 2023 Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and strat |
|
| November 9, 2023 |
As filed with the Securities and Exchange Commission on November 9, 2023 As filed with the Securities and Exchange Commission on November 9, 2023 Registration No. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 |
|
| November 9, 2023 |
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Exhibit 99.1 Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update DOYLESTOWN, PA, Nov. 9, 2023 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended Sept |
|
| November 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Aprea Therapeutics, Inc. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| October 16, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 16, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| October 16, 2023 |
Exhibit 99.1 Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio DOYLESTOWN, Pa., October 16, 2023 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precisi |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 13, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| October 13, 2023 |
Exhibit 99.1 Precision Oncology Through Synthetic Lethality October 2023 Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and strate |
|
| September 11, 2023 |
Exhibit 99.1 Precision Oncology Through Synthetic Lethality September 2023 Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and stra |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 11, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commiss |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 23, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2023 |
Exhibit 99.2 Precision Oncology through Synthetic Lethality August 2023 Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and strateg |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Apre |
|
| August 10, 2023 |
Exhibit 99.1 Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations DOYLESTOWN, PA, August 10, 2023 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and six mo |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| July 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 3, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 15, 2023 |
Exhibit 99.2 Precision Oncology through Synthetic Lethality May 2023 Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and strategic |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Apr |
|
| May 15, 2023 |
Exhibit 99.1 Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations DOYLESTOWN, PA, May 15, 2023 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 5, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 8, 2023 |
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors Exhibit 99.1 Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors DOYLESTOWN, PA, May 8 2023 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of Gab |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-390 |
|
| April 18, 2023 |
Letter from Ernst & Young LLP. Exhibit 16.1 April 18, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated April 18, 2023, of Aprea Therapeutics, Inc. and are in agreement with the statements contained in paragraphs one, three and four therein. We have no basis to agree or disagree with other statements of the registrant contained therein. |
|
| April 18, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 17, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| March 30, 2023 |
Exhibit 10.20 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) between APREA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and Oren Gilad (the “Executive”), is made and entered into as of May 16, 2022 (the “Effective Date”). WHEREAS, the Company entered into that certain Agreement and Plan of Merger by and among the Company, ATR Merger Sub I Inc., a Delaware corporati |
|
| March 30, 2023 |
Separation and General Release Agreement between Aprea Therapeutics, Inc. and Christian S. Schade. EX-10.9 3 apre-20221231xex10d9.htm EX-10.9 Exhibit 10.9 SEPARATION AND GENERAL RELEASE AGREEMENT This Separation and General Release Agreement (the “Agreement”) is made by and between Chris Schade (the “Executive”) and Aprea Therapeutics, Inc. (the “Company”) (collectively, the “Parties”). WHEREAS, the Company and Executive are parties to an Employment Agreement, dated as of September 26, 2019 (th |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 30, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| March 30, 2023 |
Employment Agreement between Aprea Therapeutics, Inc. and Eyal Attar Exhibit 10.10 Execution Copy EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) between APREA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and Eyal C. Attar, M.D. (the “Executive”), is made and entered into as of September 26, 2019, and will become effective, if at all, upon the date of closing of the Company’s initial public offering of stock pursuant to an effective |
|
| March 30, 2023 |
Retention Letter Agreement between Aprea Therapeutics, Inc. and Scott M. Coiante. EX-10.18 9 apre-20221231xex10d18.htm EX-10.18 Exhibit 10.18 Aprea Therapeutics, Inc. 535 Boylston St. Boston, MA 02116 May 16, 2022 RE: Post-Transaction Employment Dear Scott Coiante, As a critical team member and as an inducement for your to remain employed with Aprea Therapeutics, Inc. (the “Company”) following the consummation of the transactions pursuant to that certain Agreement and Plan of M |
|
| March 30, 2023 |
Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets Exhibit 99.1 Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations DOYLESTOWN, PA, March 30, 2023 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response |
|
| March 30, 2023 |
Separation and General Release Agreement between Aprea Therapeutics, Inc. and Lars Abrahmsen. Exhibit 10.13 SEPARATION AND GENERAL RELEASE AGREEMENT This Separation and General Release Agreement (the “Agreement”) is made by and between Lars Abrahmsen (the “Executive”) and Aprea Therapeutics, Inc. (the “Company”) (collectively, the “Parties”). WHEREAS, the Company and Executive are parties to an Employment Agreement, dated as of September 7, 2016 (the “Employment Agreement”); WHEREAS, the C |
|
| March 30, 2023 |
Separation and General Release Agreement between Aprea Therapeutics, Inc. and Eyal Attar. Exhibit 10.11 SEPARATION AND GENERAL RELEASE AGREEMENT This Separation and General Release Agreement (the “Agreement”) is made by and between Eyal Attar (the “Executive”) and Aprea Therapeutics, Inc. (the “Company”) (collectively, the “Parties”). WHEREAS, the Company and Executive are parties to an Employment Agreement, dated as of October [], 2019 (the “Employment Agreement”); WHEREAS, the Compan |
|
| March 30, 2023 |
Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Aprea Therapeutics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, par value $0.001 per share (the “common stock”). For purposes of this exhibit, unless the context otherw |
|
| March 30, 2023 |
Exhibit 10.19 CONFIDENTIAL SEVERANCE AGREEMENT AND GENERAL RELEASE This Confidential Severance Agreement and General Release (“Agreement”) is made by and between Scott M. Coiante (“Employee”) and Aprea Therapeutics, Inc., its subsidiaries, affiliates, successors, and assigns (“Company”) (collectively, the “Parties”). WHEREAS, Employee was employed by Company pursuant to that certain Employment Agr |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Aprea Therapeutic |
|
| March 30, 2023 |
Exhibit 10.21 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) between APREA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and John P. Hamill (the “Executive”), is made and entered into as of January 30, 2023 and shall become effective January 30, 2023 (the “Effective Date”). WHEREAS, the Company desires to employ Executive on the terms and conditions contained herein |
|
| March 30, 2023 |
Subsidiaries of Aprea Therapeutics, Inc. Exhibit 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation Aprea Therapeutics AB Sweden Aprea US, Inc. Delaware ATR Merger Sub II LLC Delaware |
|
| March 30, 2023 |
Precision Oncology through Synthetic Lethality March 2023 Exhibit 99.2 Precision Oncology through Synthetic Lethality March 2023 Forward - Looking Statements Certain information contained in this presentation includes “forward - looking statements”, within the meaning of Section 27A of t he Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinic al trials, regulatory submissions and st |
|
| March 30, 2023 |
Exhibit 10.16 March 28, 2023 Via Email Greg Korbel [email protected] Dear Greg: This Separation Agreement and General Release (this “Agreement”) will confirm the arrangements we have discussed concerning the mutual understanding reached by Aprea Therapeutics, Inc. (the “Company”) and you regarding the cessation of your employment. Subject to your execution and non-revocation of this Agreement, |
|
| March 30, 2023 |
Retention Letter Agreement between Aprea Therapeutics, Inc. and Gregory A. Korbel, Ph.D. Exhibit 10.15 Aprea Therapeutics, Inc. 535 Boylston St. Boston, MA 02116 May 16, 2022 RE: Post-Transaction Employment Dear Gregory Korbel, As a critical team member and as an inducement for your to remain employed with Aprea Therapeutics, Inc. (the “Company”) following the consummation of the transactions pursuant to that certain Agreement and Plan of Merger, dated as of May 16, 2022, by and among |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 13, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| March 3, 2023 |
APRE / Aprea Therapeutics Inc / HIRSCHMAN ORIN Passive Investment UNITED STATE SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ApreaTherapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03836J102 (CUSIP Number) February 23, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 1, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission F |
|
| March 1, 2023 |
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement DOYLESTOWN, PA, March 1, 2023 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it received formal n |
|
| February 24, 2023 |
1,050,000 Shares of Common Stock 424B5 1 tm237532d2424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-250041 PROSPECTUS SUPPLEMENT (To prospectus dated November 30, 2020) 1,050,000 Shares of Common Stock We are offering 1,050,000 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “APRE.” On February 23, 2023, the last reported sale price of the common stock on t |
|
| February 24, 2023 |
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock Exhibit 99.2 Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock DOYLESTOWN, PA., February 22, 2023 (GLOBE NEWSWIRE) Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the |
|
| February 24, 2023 |
Aprea Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Aprea Therapeutics Announces Proposed Public Offering of Common Stock DOYLESTOWN, Pa., February 22, 2023 (GLOBE NEWSWIRE) Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced it has commenced an underwritten |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissi |
|
| February 24, 2023 |
Exhibit 1.1 1,050,000 SHARES of Common Stock APREA THERAPEUTICS, INC. UNDERWRITING AGREEMENT February 22, 2023 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Maxim Group LLC 300 Park Avenue New York, NY 10022 Ladies and Gentlemen: The undersigned, Aprea Therapeutics, Inc., a company incorporated under the laws of Delaware (collectively wit |
|
| February 22, 2023 |
SUBJECT TO COMPLETION, DATED FEBRUARY 22, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-250041 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus do not co |
|
| February 14, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 10, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissi |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 10, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissi |
|
| February 13, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APREA THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Aprea Therapeutics, Inc. (hereinafter called the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as |
|
| February 13, 2023 |
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split EX-99.1 3 tm236225d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split DOYLESTOWN, PA, February 13, 2023 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced a one |
|
| February 10, 2023 |
Precision Oncology through Synthetic Lethality February 2023 Exhibit 99.1 Precision Oncology through Synthetic Lethality February 2023 Forward - Looking Statements Certain information contained in this presentation includes “forward - looking statements”, within the meaning of Section 27A of t he Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinic al trials, regulatory submissions and |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 10, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissi |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 30, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| January 30, 2023 |
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer Exhibit 99.1 Aprea Therapeutics Appoints John Hamill as Chief Financial Officer DOYLESTOWN, PA, January 30, 2023 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of John Hamill as Chief Financial Officer. Mr. |
|
| January 26, 2023 |
Exhibit 99.1 © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 1 January 24 - 26 , 2023 | Boston, MA | ddr - inhibitors - summit.com 2 Adding On to Monotherapy: Combining DDR Inhibitors January 2023 Forward - Looking Statements Certain information contained in this presentation includes “forward - looking statements”, within the meaning of Section 27A of t he Securities Act of 1933, as amended, |
|
| January 26, 2023 |
Exhibit 99.2 © 2023 Aprea Therapeutics, Inc. All Rights Reserved. 1 January 24 - 26, 2023 | Boston, MA | ddr - inhibitors - summit.com 2 Understanding DDRi’s In the Clinic: Why is Toxicity Such a Big Issue? January 2023 Forward - Looking Statements Certain information contained in this presentation includes “forward - looking statements”, within the meaning of Section 27A of t he Securities Act of |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 26, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 9, 2023 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2023 |
Precision Oncology through Synthetic Lethality January 2023 EX-99.1 2 tm232576d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Precision Oncology through Synthetic Lethality January 2023 Forward - Looking Statements Certain information contained in this presentation includes “forward - looking statements”, within the meaning of Section 27A of t he Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our c |
|
| December 15, 2022 |
As filed with the Securities and Exchange Commission on December 15, 2022 As filed with the Securities and Exchange Commission on December 15, 2022 Registration No. |
|
| December 15, 2022 |
Calculation of Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Aprea Therapeutics, Inc. |
|
| November 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 16, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissi |
|
| November 16, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissi |
|
| November 15, 2022 |
APRE / Aprea Therapeutics Inc / HealthCap VII, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Aprea Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03836J102 (CUSIP Number) HealthCap VII, L.P. Represented by its general partner HealthCap VII GP S.A. Avenue Villamont 23 Lausanne, V8 CH -1005 +4121 61 |
|
| November 9, 2022 |
Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets Exhibit 99.1 Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations BOSTON, MA, November 9, 2022 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| October 26, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| October 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| September 16, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 12, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commiss |
|
| September 2, 2022 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-250041 PROSPECTUS SUPPLEMENT DATED SEPTEMBER 2, 2022 (To Prospectus dated November 30, 2020) APREA THERAPEUTICS, INC. Up to $14,744,728 of Common Stock This Prospectus Supplement, amends and supplements the prospectus, dated November 30, 2020 (the ?ATM Prospectus?), filed as part of our registration statement on Form S-3 (File No. 333-250041 |
|
| August 19, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 15, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 11, 2022 |
Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets Exhibit 99.1 Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations BOSTON, MA, August 11, 2022 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 11, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| August 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 28, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission F |
|
| July 29, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 28, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission F |
|
| July 1, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 29, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission F |
|
| June 30, 2022 |
APRE / Aprea Therapeutics Inc / HealthCap VII, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aprea Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03836J102 (CUSIP Number) HealthCap VII, L.P. Represented by its general partner HealthCap VII GP S.A. 23 Avenue Villamont Lausanne, V8 CH -1005 +4121 61 |
|
| June 10, 2022 |
DEF 14A 1 apre-20220728xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| June 3, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 3, 2022 |
Exhibit 4.4 ATRIN PHARMACEUTICALS, LLC AMENDMENT NO. 1 TO THE 2016 AMENDED AND RESTATED EQUITY COMPENSATION PLAN February 2, 2022 WHEREAS, Atrin Pharmaceuticals, LLC, a Pennsylvania limited liability company (the ?Company?) maintains its 2016 Amended and Restated Equity Compensation Plan (the ?Plan?); WHEREAS, the Board of Managers of the Company (the ?Board?) and the members of the Company have a |
|
| June 3, 2022 |
EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Aprea Therapeutics, Inc. |
|
| June 3, 2022 |
Exhibit 4.3 ATRIN PHARMACEUTICALS LLC 2016 AMENDED AND RESTATED EQUITY COMPENSATION PLAN ATRIN PHARMACEUTICALS LLC 2016 AMENDED AND RESTATED EQUITY COMPENSATION PLAN The purpose of the Atrin Pharmaceuticals LLC 2016 Amended and Restated Equity Compensation Plan (the ?Plan?) is to provide (i) designated employees and officers of Atrin Pharmaceuticals LLC, a limited liability company organized under |
|
| May 27, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a party other than the Registrant ? ? ? Check the appropriate box: ????Preliminary Proxy Statement ????Confidential, for Use of the Commission Only (as permitted |
|
| May 17, 2022 |
Precision Oncology Through Synthetic Lethality May 2022 Exhibit 99.1 Precision Oncology Through Synthetic Lethality May 2022 Forward - Looking Statements Certain information contained in this presentation includes ? forward - looking statements ? , within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended, related to our clinical trials, regulatory submissions and |
|
| May 17, 2022 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: APREA THERAPEUTICS, INC., a Delaware corporation; ATR MERGER SUB I INC., a Delaware corporation; ATR MERGER SUB II LLC, a Delaware limited liability company; and ATRIN PHARMACEUTICALS INC., a Delaware corporation Dated as of May 16, 2022 TABLE OF CONTENTS Page Section 1. DESCRIPTION OF TRANSACTION 3 1.1. The Mergers 3 1.2. Effects of the Mergers 3 1. |
|
| May 17, 2022 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION APREA THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Aprea Therapeutics, Inc., a Delaware corporation (the ?Corporation?), that the following |
|
| May 17, 2022 |
Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is dated as of May 16, 2022, by and among Aprea Therapeutics, Inc., a Delaware corporation (the ?Company?), and the several purchasers signatory hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). This Agreement is made pursuant to the Agreement and Pl |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2022 Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission F |
|
| May 16, 2022 |
Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets Exhibit 99.1 Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results BOSTON, MA, May 16, 2022 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Phar |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2022 Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission F |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 2, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2022 |
Exhibit 21.1 Subsidiaries ? ? ? Subsidiary Jurisdiction of Incorporation Aprea Therapeutics AB ? Sweden Aprea US, Inc. ? Delaware ? |
|
| March 15, 2022 |
Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets Exhibit 99.1 Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations BOSTON, MA, March 15, 2022 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 15, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2022 |
APRE / Aprea Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) APREA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03836J102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.001 par value per share, of Aprea Therapeutics, In |
|
| February 11, 2022 |
APRE / Aprea Therapeutics Inc / Versant Ventures V, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2) Aprea Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03836J102 (CUSIP Number) Dece |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 13, 2022 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| January 13, 2022 |
J.P. Morgan 40 th Annual Healthcare Conference January 2022 Exhibit 99.1 J.P. Morgan 40 th Annual Healthcare Conference January 2022 Forward - Looking Statements Certain information contained in this presentation includes ?forward - looking statements?, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and st |
|
| December 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 9, 2021 (December 8, 2021) Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorp |
|
| December 9, 2021 |
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies Exhibit 99.1 Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies BOSTON, MA, December 9, 2021 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug A |
|
| November 9, 2021 |
As filed with the Securities and Exchange Commission on November 8, 2021 As filed with the Securities and Exchange Commission on November 8, 2021 Registration No. |
|
| November 8, 2021 |
Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets (Unaudited) Exhibit 99.1 Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations BOSTON, MA, November 8, 2021 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 8, 2021 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 15, 2021 |
APRE / Aprea Therapeutics Inc / HealthCap VII, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aprea Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03836J102 (CUSIP Number) HealthCap VII, L.P. Represented by its general partner HealthCap VII GP S.A. 18 Avenue d’Ouchy Lausanne, V8 CH -1006 + |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 13, 2021 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 12, 2021 |
Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets Exhibit 99.1 Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations BOSTON, MA, August 12, 2021 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2021 (August 11, 2021) Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorpor |
|
| August 12, 2021 |
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program Exhibit 99.2 Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program BOSTON, MA, August 12, 2021 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed |
|
| August 6, 2021 |
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs Exhibit 99.1 Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs BOSTON, MA, August 5, 2021 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) h |
|
| August 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 5, 2021 (August 4, 2021) Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporat |
|
| June 10, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2021 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2021 |
Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets Exhibit 99.1 Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations BOSTON, MA, May 6, 2021 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the t |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2021 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ????Preliminary Proxy Statement ????Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| April 28, 2021 |
DEF 14A 1 apre-20210609xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| March 16, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 16, 2021 |
Aprea Therapeutics, Inc. Condensed Consolidated Balance Sheets Exhibit 99.1 Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations BOSTON, MA, March 16, 2021 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial |
|
| March 16, 2021 |
Exhibit 21.1 Subsidiaries ? ? ? Subsidiary Jurisdiction of Incorporation Aprea Therapeutics AB ? Sweden Aprea Personal AB ? Sweden Aprea US, Inc. ? Delaware ? |
|
| March 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 16, 2021 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commission |
|
| March 16, 2021 |
Exhibit 4.1 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Aprea Therapeutics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): its common stock, par value $0.001 per share (the ?common stock?). For purposes of this exhibit, unless the context otherw |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Aprea Therapeutics, In |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) APREA THERAPEUTICS, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03836J102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* Aprea Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03836J102 (CUSIP Number) Rebecca Lucia |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1) Aprea Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03836J102 (CUSIP Num |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) APREA therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03836J102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* APREA THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03836J102 (CUSIP Number) DECEMBER 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 12, 2021 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissio |
|
| January 12, 2021 |
J.P. Morgan 39 th Annual Healthcare Conference January 2021 Exhibit 99.1 J.P. Morgan 39 th Annual Healthcare Conference January 2021 Forward - Looking Statements Certain information contained in this presentation includes “forward - looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials and regulatory submissions. We |
|
| December 28, 2020 |
Exhibit 99.1 Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS) - The trial failed to meet its primary endpoint of complete remission (CR) rate - CR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach statistical significance BOSTON, MA, December 28, 2020 (GLOBE NEWSWIRE) - |
|
| December 28, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 28, 2020 Date of Report (Date of earliest event reported) Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39069 84-2246769 (State or other jurisdiction of incorporation) (Commissi |
|
| November 25, 2020 |
November 25, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jason Drory Re: Acceleration Request for Aprea Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-250041) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the |
|
| November 24, 2020 |
As filed with the Securities and Exchange Commission on November 24, 2020. Registration No. 333-250041 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APREA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-2246769 (State or other jurisdiction of (I.R.S. E |
|
| November 19, 2020 |
APRE / Aprea Therapeutics Inc / 5AM Ventures IV, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Aprea Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03836J102 (CUSIP Number) Rebecca Lucia |
|
| November 12, 2020 |
Form S-8 (SEC File No. 333-250043) As filed with the Securities and Exchange Commission on November 12, 2020 Registration No. |
|
| November 12, 2020 |
Sales Agreement, dated as of November 12, 2020, between the Registrant and SVB Leerink LLC. Exhibit 1.2 Aprea Therapeutics, Inc. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT November 12, 2020 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows: 1. Issuance and Sa |
|
| November 12, 2020 |
Exhibit 4.1 APREA THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series 4 Section 2.2. Establi |
|
| November 12, 2020 |
As filed with the Securities and Exchange Commission on November 12, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APREA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-2246769 (State or other jurisdiction of (I.R.S. Employer incorporation or |
